Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Adicet Bio, Inc. (Nasdaq: ACET) reported significant progress, including the IND clearance and initiation of its first-in-human Phase 1 trial for ADI-001, targeting B cell non-Hodgkin’s lymphoma. The company raised $143.6 million through a public offering to support its pipeline of CAR gamma-delta T cell therapies. For 2020, R&D expenses rose to $34.3 million, while G&A expenses hit $22.8 million. The net loss for the year was $36.7 million, or $5.01 per share, up from 2019's $28.1 million. Cash and marketable securities totaled $94.6 million at year-end, ensuring operational funding into 2023.
Adicet Bio (Nasdaq: ACET) has initiated its First-in-Human Phase I clinical trial for ADI-001, an innovative allogeneic gamma delta T cell therapy aimed at treating B cell non-Hodgkin's lymphoma (NHL). This open-label trial will enroll around 75 patients diagnosed with relapsed or refractory B cell malignancies. The primary focus is on evaluating ADI-001's safety, tolerability, and pharmacodynamics, with preliminary results expected by late 2021. The therapy's potential, based on encouraging preclinical data, suggests it could provide a new treatment option for NHL patients.
Adicet Bio, Inc. (Nasdaq: ACET) announced the appointment of Andrew Sinclair, Ph.D., to its board of directors, succeeding Erez Chimovits. Sinclair, a partner at Abingworth, brings significant life sciences investment experience, particularly related to biotechnology and pharmaceuticals. His addition follows a successful $152 million financing, highlighting investor confidence. The company aims to advance its gamma delta T cell therapies, with a focus on clinical development and expanding its product pipeline, addressing cancer and other diseases.
Adicet Bio, Inc. (Nasdaq: ACET) has successfully closed an underwritten public offering of 10,575,513 shares of common stock at a price of $13.00 per share, generating approximately $137.5 million in gross proceeds. This includes the full exercise of an option by underwriters to purchase an additional 1,344,743 shares. Additionally, Adicet has entered into a stock purchase agreement with existing investors for $15.0 million in shares at the public offering price. The offering is conducted under a previously filed shelf registration statement with the SEC.
Adicet Bio, Inc. (Nasdaq: ACET) has announced participation in three virtual investor conferences: Guggenheim Healthcare Talks (Feb 11-12), SVB Leerink Global Healthcare Conference (Feb 22-26), and H.C. Wainwright Global Life Sciences Conference (Mar 9-10). CEO Chen Schor will present on Feb 24 at 5:00 PM ET during the SVB Leerink Conference. A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days. Adicet specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases.
Adicet Bio (ACET) announced a public offering of 9,230,770 shares at $13.00 per share, aiming to raise gross proceeds of approximately $120 million. The offering includes a 30-day option for underwriters to buy an additional 1,344,743 shares. The expected closing date is February 12, 2021. Concurrently, Adicet plans a $15 million private placement with existing investors at the same price per share. Guggenheim Securities is the book-running manager for the offering.
Adicet Bio, Inc. (Nasdaq: ACET) announced an underwritten public offering of its common stock, aiming to raise funds for its allogeneic gamma delta T cell therapies for cancer. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. Adicet will enter into a stock purchase agreement with existing investors for $15 million in common stock at the public offering price, with initial and subsequent closings planned. The offering's completion is contingent on market conditions and other factors.
Adicet Bio, Inc. (Nasdaq: ACET) announced participation in two upcoming virtual investor conferences in January 2021. The first, the H.C. Wainwright Bioconnect 2021 Conference, will offer an on-demand presentation beginning January 11, 2021, at 6:00 AM ET. The second event, the B. Riley Securities' Oncology Investor Conference, features a fireside chat on January 20, 2021, at 3:30 PM ET. Both presentations will be accessible via the company’s website. Adicet Bio specializes in developing allogeneic gamma delta T cell therapies for cancer and other diseases.
Adicet Bio (Nasdaq: ACET), a biotechnology firm specializing in allogeneic gamma delta T cell therapies, announced participation in a fireside chat at The JMP Securities Hematology Summit on December 15, 2020, at 2:00 PM ET. The discussion will be led by Chen Schor, CEO, and Stewart Abbot, Ph.D., COO. Investors can access a live audio webcast on the company’s website, followed by a 30-day archive. Adicet's innovative therapies aim to enhance tumor targeting and improve immune responses for cancer treatment.
Adicet Bio, Inc. (Nasdaq: ACET) has appointed Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna, currently at Vertex Pharmaceuticals, is recognized for his extensive experience in cell therapy. His previous roles include CEO of Semma Therapeutics and Global Program Head at Novartis. The addition of Dr. Sanna is expected to strengthen Adicet’s pipeline, particularly in advancing ADI-001, their allogeneic gamma delta T cell therapy. Adicet focuses on innovative cancer treatments through enhanced immune response and tumor targeting.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
What is Adicet Bio, Inc.?
What are the key products in Adicet Bio's pipeline?
What recent achievements has Adicet Bio made?
How is Adicet Bio financially positioned?
What strategic collaborations has Adicet Bio entered into?
What is the focus of Adicet Bio's research and development?
What are ADI-001 and ADI-270?
What makes Adicet Bio's approach unique?
What is the significance of the FDA's fast track designation for ADI-001?
Where can I find more information about Adicet Bio?
